Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2005 08:00 ET | Source: VioQuest Pharmaceuticals

VioQuest to Present at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference

MONMOUTH JUNCTION, N.J., Oct. 20, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH) has accepted an invitation to speak at the C.E. Unterberg, Towbin Emerging Growth Life Sciences...
October 19, 2005 08:00 ET | Source: VioQuest Pharmaceuticals

VioQuest Completes Merger with Greenwich Therapeutics; Acquires Oncology Compounds

Raises $8.4 Million in Private Placement Acquisition Establishes Strong Pipeline of Phase I/II Targeted Oncology Therapeutics MONMOUTH JUNCTION, N.J. Oct. 19,...
October 17, 2005 10:28 ET | Source: VioQuest Pharmaceuticals

VioQuest to Present at BIO InvestorForum 2005

MONMOUTH JUNCTION, N.J., Oct. 17, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc., (OTCBB:VQPH), will be presenting at the BIO InvestorForum 2005 Conference at 11:20 AM PST Thursday, October 20th...
October 12, 2005 09:10 ET | Source: VioQuest Pharmaceuticals

VioQuest Pharmaceuticals Named One of 50 Fastest Growing Companies in New Jersey by 'New Jersey's Finest'

MONMOUTH JUNCTION, N.J., Oct. 12, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc., (OTCBB:VQPH) was named among "New Jersey's 50 Finest" by NJBIZ Magazine. The Company was honored in an awards...
October 05, 2005 08:00 ET | Source: VioQuest Pharmaceuticals

VioQuest Pharmaceuticals Reports 45 Percent Increase in Revenue for Fiscal Third Quarter 2005

MONMOUTH JUNCTION, N.J., Oct. 5, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH) reported revenue of approximately $533,000 for the third quarter of 2005 compared to $367,000 for the...
September 15, 2005 08:00 ET | Source: VioQuest Pharmaceuticals

VioQuest Pharma Subsidiary Signs License Agreement with Merck to Supply Chiral Catalysts and Ligands

MONMOUTH JUNCTION, N.J., Sept. 15, 2005 (PRIMEZONE) -- VioQuest's subsidiary Chiral Quest, Inc., (OTCBB:VQPH) signed a licensing agreement granting Merck & Co., Inc. use of its catalysts for the...
September 13, 2005 09:10 ET | Source: VioQuest Pharmaceuticals

VioQuest's Proposed Drug Acquisition Candidate Enters Phase I Clinical Trial at Cleveland Clinic Cancer Center

MONMOUTH JUNCTION, N.J, Sept. 13, 2005 (PRIMEZONE) -- The Cleveland Clinic Taussig Cancer Center has initiated patient enrollment for a Phase I clinical trial of sodium stibogluconate (SSG), an...